Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 72

Sort by

Sort Order Select

Journal Articles

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-139345

Published: 2020

Journal Articles

CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction

Dongzheng Gai, MD, Stewart JP, Xuxing Shen, Jin-Ran Chen, PhD, Can Li, MD, Bailu Peng, PhD, Ya-Wei Qiang, MD PhD, Shmuel Yaccoby, PhD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Guido J. Tricot, MD PhD, Lijuan Chen, MDPhD, John Shaughnessy, Jr., PhD, Fenghuang Zhan, MD PhD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-140568

Published: 2020

Journal Articles

Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma

Xuelian Tan, Timothy Cody Ashby, PhD, Yuqi Zhu, Can Li, MD, Xuxing Shen, MBBS, Qierra Brockman, BA, Dongzheng Gai, MD, Sarah K Johnson, PhD, Donghoon Yong, Carolina D. Schinke, MD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, John Shaughnessy, Jr., PhD, Dingming Huang, PhD, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-140372

Published: 2020

Journal Articles

Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma

Can Li, MD, Xuelian Tan, Qierra Brockman, BA, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Marta Chesi, PhD, P. Leif Bergsagel, MD, Fangping Chen, MD PhD, Ivana Frech, DSc, PhD MBA, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 3059.

https://doi.org/10.1182/blood-2019-123473

Published: 2019

Journal Articles

Targeting NEK2 Induces Cellular Senescence in B-Cell Malignancies through p53-Independent Signaling Pathways

Yuqi Zhu, Ye Yang, PhD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 3102.

https://doi.org/10.1182/blood-2019-123815

Published: 2019

Journal Articles

1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma

Chenxing Du, An Gang, MD, Yan Xu, Xuehan Mao, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, MD, Li Zengjun, Chengwen Li, Shuhua Yi, MD, Mu Hao, Dehui Zou, MD, Fenghuang Zhan, MD PhD, Yu-Tzu Tai, PhD, Kenneth C. Anderson, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 4343.

https://doi.org/10.1182/blood-2019-129739

Published: 2019

Journal Articles

Development of an Easily Accessible Patient-Derived Xenograft (PDX) Mouse Model in Multiple Myeloma

Can Li, MD, Yogesh Jethava, MBBS, MDFRCPath, MRCP, Ivana Frech, DSc, PhD MBA, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 5538.

https://doi.org/10.1182/blood-2019-121933

Published: 2019

Journal Articles

TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression

Can Li, MD, Reinaldo Franqui-Machin, Jiliang Xia, PhD, Gregory S. Thomas, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Fangping Chen, MD PhD, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 854.

https://doi.org/10.1182/blood-2019-123818

Published: 2019

Journal Articles

Single-Cell Analysis Reveals Sequential Genetic Events from Hematopoietic Stem Cell Differentiation Hierarchy in Multiple Myeloma Patients with FGFR3/IGH Translocation

Wen Zhou, PhD, Fenghuang Zhan, MD PhD

Blood (2018) 132 (Supplement 1): 5598.

https://doi.org/10.1182/blood-2018-99-115606

Published: 2018

Journal Articles

High Expression of NEK2 Mediated By p53 Contributes to Progression and Relapse of Multiple Myeloma

Wen Zhou, PhD, Fenghuang Zhan, MD PhD

Blood (2018) 132 (Supplement 1): 192.

https://doi.org/10.1182/blood-2018-192

Published: 2018

Journal Articles

Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience

Kalyan Nadiminti, MD, Christopher Strouse, MD, Praveen Vikas, MD, Lindsay Dozeman, Allyson Schultz, Sarah L Mott, Jillna Claus, Umar Farooq, MD, Margarida Silverman, MD, Michael Tomasson, MD, Fenghuang Zhan, MD PhD, Yogesh Jethava, MBBS, MDFRCPath, MRCP, Guido J. Tricot, MD PhD

Blood (2018) 132 (Supplement 1): 2152.

https://doi.org/10.1182/blood-2018-99-113890

Published: 2018

Journal Articles

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)

Kalyan Nadiminti, MD, Christopher Strouse, MD, Praveen Vikas, MD, Lindsay Dozeman, Allyson Schultz, Gabrielle Berns, Jillna Claus, Sarah L Mott, Umar Farooq, MD, Margarida Silverman, MD, Michael Tomasson, MD, Fenghuang Zhan, MD PhD, Yogesh Jethava, MBBS, MD FRCPath, MRCP

Blood (2018) 132 (Supplement 1): 2153.

https://doi.org/10.1182/blood-2018-99-118443

Published: 2018

Journal Articles

The Nek2 Genetic Knockout Mouse Model Provides Novel Treatment Strategies in Myeloma and Lymphoma

Li Can, MD, Kalyan Nadiminti, Yuqi Zhu, Yogesh Jethava, MBBS, MD FRCPath, MRCP, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2018) 132 (Supplement 1): 5612.

https://doi.org/10.1182/blood-2018-99-115099

Published: 2018

Journal Articles

Potential Metabolite Markers of Multiple Myeloma

Jiliang Xia, PhD, Jingyu Zhang, Xuan Wu, ShiLian Chen, Jingchao Lin, Mingming Su, Jiaojiao Guo, Yongjun Guan, Minghua Wu, Lugui Qiu, MD, Fenghuang Zhan, MD, Wen Zhou, PhD

Blood (2018) 132 (Supplement 1): 3163.

https://doi.org/10.1182/blood-2018-99-115934

Published: 2018

Journal Articles

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy Is Safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective Phase II Trial (NCT01849783)

Kalyan Nadiminti, MD, Lindsay Dozeman, Annick Tricot, Allyson Schultz, Sheila Ouverson, Fenghuang Zhan, MD PhD, Margarida Silverman, MD, Guido J. Tricot, MD PhD, Yogesh Jethava, MBBS,MDFRCPath,MRCP

Blood (2017) 130 (Supplement 1): 4543.

https://doi.org/10.1182/blood.V130.Suppl_1.4543.4543

Published: 2017

Journal Articles

Clinical Investigation of Mitochondrial Biogenesis in Multiple Myeloma

Xin Zhan, Reinaldo Franqui-Machin, Kalyan Nadiminti, MD, Huojun Cao, Brad A. Amendt, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Ivana Frech, DSc, PhD MBA, Fenghuang Zhan, MD PhD, Guido J. Tricot, MD PhD

Blood (2017) 130 (Supplement 1): 1785.

https://doi.org/10.1182/blood.V130.Suppl_1.1785.1785

Published: 2017

Journal Articles

The Interaction of NEK2 with USP7 Causes Resistance to Proteasome Inhibitor in Multiple Myeloma

Reinaldo Franqui-Machin, Mu Hao, PhD, Bai Hua, Zhimin Gu, PhD, Xin Zhan, Hongwei Xu, Hasem Habelhah, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Lugui Qiu, MD, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2017) 130 (Supplement 1): 593.

https://doi.org/10.1182/blood.V130.Suppl_1.593.593

Published: 2017

Journal Articles

Multiple Myeloma Tumor Cells Are Selectively Killed By Pharmacologically-Dosed Ascorbic Acid

Reinaldo Franqui-Machin, Hongwei Xu, Yogesh Yethava, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2017) 130 (Supplement 1): 5391.

https://doi.org/10.1182/blood.V130.Suppl_1.5391.5391

Published: 2017

Journal Articles

Nek2 Stabilization By Usp7 Leads to Activation of NF-Kb in Multiple Myeloma

Reinaldo Franqui Machin, BS, Xin Zhan, BA, Hongwei Xu, DDS, Ivana Frech, DSc, PhD MBA, Guido J Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2016) 128 (22): 4418.

https://doi.org/10.1182/blood.V128.22.4418.4418

Published: 2016

Journal Articles

Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis

Mu Hao, MD PhD, Meirong Zang, PhD, Yan Xu, MDPhD, Yu Qin, MD PhD, Lei Zhao, MD PhD, Shuhui Deng, MD PhD, Weiwei Sui, MD, Gang An, MDPhD, Zengjun Li, MD PhD, Yi Shuhua, MD PhD, Fenghuang Zhan, MD PhD, Lugui Qiu, MD PhD

Blood (2015) 126 (23): 4186.

https://doi.org/10.1182/blood.V126.23.4186.4186

Published: 2015

NARROW

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction

Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma

Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma

Targeting NEK2 Induces Cellular Senescence in B-Cell Malignancies through p53-Independent Signaling Pathways

1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma

Development of an Easily Accessible Patient-Derived Xenograft (PDX) Mouse Model in Multiple Myeloma

TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression

Single-Cell Analysis Reveals Sequential Genetic Events from Hematopoietic Stem Cell Differentiation Hierarchy in Multiple Myeloma Patients with FGFR3/IGH Translocation

High Expression of NEK2 Mediated By p53 Contributes to Progression and Relapse of Multiple Myeloma

Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)

The Nek2 Genetic Knockout Mouse Model Provides Novel Treatment Strategies in Myeloma and Lymphoma

Potential Metabolite Markers of Multiple Myeloma

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy Is Safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective Phase II Trial (NCT01849783)

Clinical Investigation of Mitochondrial Biogenesis in Multiple Myeloma

The Interaction of NEK2 with USP7 Causes Resistance to Proteasome Inhibitor in Multiple Myeloma

Multiple Myeloma Tumor Cells Are Selectively Killed By Pharmacologically-Dosed Ascorbic Acid

Nek2 Stabilization By Usp7 Leads to Activation of NF-Kb in Multiple Myeloma

Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only